Skip to content

A clinical trial to evaluate the efficacy and safety of defocusing lenses in delaying myopia progression

A clinical trial to evaluate the efficacy and safety of defocusing lenses in delaying myopia progression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098370
Enrollment
Unknown
Registered
2025-03-06
Start date
2024-04-10
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nearsightedness

Interventions

Test group A:12-month defocusing lens (Microstructured Lens A)
Test group B:12-month defocusing lens (Microstructured Lens B)
Control group:Wear aspherical lenses for 12 months

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 13 Years

Inclusion criteria

Inclusion criteria: (1) Age 8~13 years old (including boundary values), gender is not limited; (2) The spherical degree of subjective optometry in both eyes with cycloplegic muscle paralysis was between -1.00D and -6.00D (including the boundary value) (based on the mean value of subjective optometry), and the equivalent spherical difference of both eyes was less than 1.50D; (3) Optimal corrected visual acuity >=1.0 in left and right eye after ciliary muscle paralysis; (4) In both eyes with cycloplegia, the degree of the column lens was <=1.50 days; (5) Voluntarily participate in the clinical study, sign the informed consent, and obtain the written consent of the guardian.

Exclusion criteria

Exclusion criteria: (1) Have a history of eye trauma or intraocular surgery; (2) Abnormal results of slit-lamp examination (see Annex 1 for details); (3) fundus examination results >= grade 2 (see Annex 1 for details); (4) Intraocular pressure 21mmHg or intraocular pressure difference >= 5mmHg; (5) Patients with other eye diseases, such as uveitis and other inflammation, glaucoma, cataract, fundus disease, eye tumors, eye trauma, dominant strabismus, and any eye lesions affecting visual function; (6) Associated diseases that may affect the eye (such as acute and chronic sinusitis, diabetes, Down syndrome, rheumatoid arthritis, etc.); (7) suffering from a mental disorder or other disease that the researcher deems unsuitable for wearing frame glasses; (8) Use specially designed myopia control lenses such as hard contact lenses (including care products), multifocal contact lenses, progressive multifocal lenses, and atropine drugs within 1 month before screening or during the planned study period; (9) Participating in other clinical trials within 3 months prior to screening; (10) Those who cannot perform regular eye examination; (11) Other investigators consider it inappropriate to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
Change value of equivalent spherical lens after cycloplegia (subjective refraction);

Secondary

MeasureTime frame
Spherical equivalent after cycloplegia (subjective refraction);Axial length;Regulating sensitivity;Stereopsis;Corneal curvature;Subjective perception rating for wearing a mirror;

Countries

China

Contacts

Public ContactYao Jingyan

The First Affiliated Hospital of Soochow University

yaojingyan@suda.edu.cn+86 138 6257 8532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026